ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,724.30
-0.33%
S&P ASX All Technology
3,092.70
-1.13%
Brent Oil
82.675
0.85%
US Dollar vs AUD
1.51126
0.24%
Bitcoin
65,482.40
-1.91%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. ImmunoPrecise Antibodies Ltd (IPA)

  7. ImmunoPrecise Antibodies Ltd (IPA) News

IPA

ImmunoPrecise Antibodies (IPA)

ImmunoPrecise Antibodies Ltd
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:IPA
DateTimeSourceHeadlineSymbolCompany
13/06/202403:01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPAImmunoPrecise Antibodies Ltd
12/06/202421:00Business WireBioStrand, filiale d’ImmunoPrecise Antibodies Ltd., reçoit le prestigieux prix Impact 2024 pour sa technologie LENSai™ révolutionnaireNASDAQ:IPAImmunoPrecise Antibodies Ltd
12/06/202421:00Business WireImmunoPrecise Antibodies Ltd. Subsidiary BioStrand Receives Prestigious 2024 Impact Award for Groundbreaking LENSai™ TechnologyNASDAQ:IPAImmunoPrecise Antibodies Ltd
11/06/202404:23Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPAImmunoPrecise Antibodies Ltd
11/06/202401:34Business WireBioStrand, filiale d’ImmunoPrecise Antibodies, annonce la disponibilité commerciale immédiate de son logiciel révolutionnaire doté d’une interface personnalisable pour la découverte de médicaments optimisée par l’IANASDAQ:IPAImmunoPrecise Antibodies Ltd
10/06/202421:15Business WireBioStrand, ImmunoPrecise Antibodies’ Subsidiary, Announces Immediate Commercial Offering of Groundbreaking Software with Customizable Interface for AI-Driven Drug DiscoveryNASDAQ:IPAImmunoPrecise Antibodies Ltd
05/06/202407:01Business WireLa filiale d’IPA, BioStrand, annonce un LLM avancé pour les dossiers de santé électroniquesNASDAQ:IPAImmunoPrecise Antibodies Ltd
05/06/202406:11Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPAImmunoPrecise Antibodies Ltd
04/06/202421:00Business WireIPA’s Subsidiary, BioStrand, Announces Advanced Large Language Model (LLM) for Electronic Health Records (EHR)NASDAQ:IPAImmunoPrecise Antibodies Ltd
29/03/202405:35Business WireInterSystems et BioStrand, filiale d’IPA, collaborent au lancement de l’intégration innovante de la recherche vectorielle et de LENSai dans les applications de soins de santé pilotées par l’IANASDAQ:IPAImmunoPrecise Antibodies Ltd
28/03/202422:02Business WireInterSystems and IPA’s Subsidiary BioStrand Collaborate to Unveil the Innovative Integration of Vector Search with LENSai for AI-Driven Healthcare ApplicationsNASDAQ:IPAImmunoPrecise Antibodies Ltd
21/03/202404:52Business WireIPA acquiert l'instrument Carterra LSA® pour améliorer la découverte d'anticorps et renforcer ses développements en matière d'IANASDAQ:IPAImmunoPrecise Antibodies Ltd
20/03/202422:02Business WireIPA Acquires the Carterra LSA® Instrument to Enhance Antibody Discovery and Bolster Its AI DevelopmentsNASDAQ:IPAImmunoPrecise Antibodies Ltd
15/03/202410:39Business WireIPA présente ses résultats financiers et les récents points forts de son activité pour le troisième trimestre de l’exercice 2024*NASDAQ:IPAImmunoPrecise Antibodies Ltd
14/03/202423:05Business WireIPA Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024*NASDAQ:IPAImmunoPrecise Antibodies Ltd
08/03/202407:24Business WireBioStrand, filiale d'IPA, annonce une avancée majeure dans les sciences du vivant avec son Advanced Foundation AI Model utilisant l'empilement LLM et la technologie HYFTNASDAQ:IPAImmunoPrecise Antibodies Ltd
08/03/202403:19Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPAImmunoPrecise Antibodies Ltd
07/03/202423:02Business WireIPA’s subsidiary BioStrand Unveils Major Breakthrough in Life Sciences with Advanced Foundation AI Model Utilizing LLM Stacking and HYFT TechnologyNASDAQ:IPAImmunoPrecise Antibodies Ltd
05/03/202408:50Business WireL'IPA publiera ses résultats financiers et les faits marquants de sa récente activité pour le troisième trimestre de l'exercice 2024, le 14 mars 2024NASDAQ:IPAImmunoPrecise Antibodies Ltd
05/03/202400:01Business WireIPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024 on March 14, 2024NASDAQ:IPAImmunoPrecise Antibodies Ltd
24/02/202409:29Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPAImmunoPrecise Antibodies Ltd
24/02/202409:26Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:IPAImmunoPrecise Antibodies Ltd
16/02/202407:12Edgar (US Regulatory)Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]NASDAQ:IPAImmunoPrecise Antibodies Ltd
11/01/202405:53Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:IPAImmunoPrecise Antibodies Ltd
11/01/202405:33Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:IPAImmunoPrecise Antibodies Ltd
15/12/202307:08Business WireIPA présente ses résultats financiers et les récents points forts de son activité pour le deuxième trimestre de l’exercice 2024*NASDAQ:IPAImmunoPrecise Antibodies Ltd
15/12/202300:48Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPAImmunoPrecise Antibodies Ltd
15/12/202300:38Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPAImmunoPrecise Antibodies Ltd
15/12/202300:03Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPAImmunoPrecise Antibodies Ltd
15/12/202300:01Business WireIPA Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2024*NASDAQ:IPAImmunoPrecise Antibodies Ltd
 Showing the most relevant articles for your search:NASDAQ:IPA

Your Recent History

ASX
WOW
Woolworths
ASX
CBA
Commonwealth Bank Of Aus...
ASX
XMM
S&P ASX 300 Metals and M...
FX
GBPAUD
Sterling vs AUD
NASDAQ
AMZN
Amazon.com
ASX
XJO
S&P ASX 200
ASX
ORG
Origin Energy
ASX
MQG
Macquarie
ASX
NCM
Newcrest Mining
ASX
AMP
AMP
SPI
SP500
S&P 500
ASX
XTO
S&P ASX 100
COIN
ETHUSD
Ethereum
ASX
WDC
Westfield
ASX
XFL
S&P ASX 50
NYSE
VZ
Verizon Communications
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved